US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
KR890002631B1
(ko)
|
1984-10-04 |
1989-07-21 |
몬산토 캄파니 |
생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
US5612059A
(en)
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
US5798119A
(en)
|
1995-06-13 |
1998-08-25 |
S. C. Johnson & Son, Inc. |
Osmotic-delivery devices having vapor-permeable coatings
|
DE69632684T2
(de)
|
1995-06-27 |
2005-06-09 |
Takeda Pharmaceutical Co. Ltd. |
Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
US6139865A
(en)
|
1996-10-01 |
2000-10-31 |
Eurand America, Inc. |
Taste-masked microcapsule compositions and methods of manufacture
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
ATE272394T1
(de)
|
1996-10-31 |
2004-08-15 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter freisetzung
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
DE69719367T2
(de)
|
1996-12-20 |
2003-10-16 |
Takeda Chemical Industries, Ltd. |
Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
US6350458B1
(en)
|
1998-02-10 |
2002-02-26 |
Generex Pharmaceuticals Incorporated |
Mixed micellar drug deliver system and method of preparation
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
AU2001276608A1
(en)
|
2000-08-30 |
2002-03-13 |
Pfizer Products Inc. |
Sustained release formulations for growth hormone secretagogues
|
DE60117605T2
(de)
|
2000-12-21 |
2006-12-07 |
Bristol-Myers Squibb Co. |
Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
US20060183746A1
(en)
|
2003-06-04 |
2006-08-17 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
US7393848B2
(en)
|
2003-06-30 |
2008-07-01 |
Cgi Pharmaceuticals, Inc. |
Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
|
AU2004260689B8
(en)
|
2003-07-29 |
2008-05-15 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
US20050288295A1
(en)
|
2003-11-11 |
2005-12-29 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
|
SG159549A1
(en)
|
2004-11-10 |
2010-03-30 |
Cgi Pharmaceuticals Inc |
Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
|
KR20070095952A
(ko)
|
2004-12-16 |
2007-10-01 |
버텍스 파마슈티칼스 인코포레이티드 |
염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Tec 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
|
ES2543607T3
(es)
|
2005-03-10 |
2015-08-20 |
Gilead Connecticut, Inc. |
Ciertas amidas sustituidas, método de obtención, y método de su uso
|
JP2009507792A
(ja)
|
2005-08-29 |
2009-02-26 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン
|
JP2009506123A
(ja)
|
2005-08-29 |
2009-02-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン
|
CA2636696A1
(en)
|
2006-01-13 |
2007-08-02 |
Pharmacyclics, Inc. |
Inhibitors of tyrosine kinases and uses thereof
|
CA2858520A1
(en)
|
2006-05-18 |
2007-11-29 |
Pharmacyclics Inc. |
Intracellular kinase inhibitors
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
Novartis Ag |
吡咯并嘧啶化合物及其用途
|
EP2068849A2
(en)
|
2006-09-11 |
2009-06-17 |
CGI Pharmaceuticals, Inc. |
Kinase inhibitors, and methods of using and identifying kinase inhibitors
|
AR063946A1
(es)
|
2006-09-11 |
2009-03-04 |
Cgi Pharmaceuticals Inc |
Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
AR063706A1
(es)
|
2006-09-11 |
2009-02-11 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
AR063707A1
(es)
|
2006-09-11 |
2009-02-11 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
|
ES2537399T3
(es)
|
2006-09-22 |
2015-06-08 |
Pharmacyclics, Inc. |
Inhibidores de tirosina cinasa de Bruton
|
EP2076128A4
(en)
|
2006-10-06 |
2011-01-05 |
|
PROTEIN CHINESE INHIBITOR AND ITS USE METHOD
|
WO2008054827A2
(en)
|
2006-11-03 |
2008-05-08 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
WO2008116064A2
(en)
|
2007-03-21 |
2008-09-25 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
|
BRPI0810086B1
(pt)
|
2007-03-28 |
2021-11-09 |
Pharmacyclics Llc |
Composto inibidor de tirosina quinase de bruton, uso do referido composto e composição farmacêutica
|
WO2008144253A1
(en)
|
2007-05-14 |
2008-11-27 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
CL2008002793A1
(es)
|
2007-09-20 |
2009-09-04 |
Cgi Pharmaceuticals Inc |
Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
|
CN101902911B
(zh)
|
2007-10-19 |
2015-12-16 |
阿维拉制药公司 |
杂芳基化合物和其用途
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
CA2909988A1
(en)
|
2007-10-23 |
2009-04-30 |
F. Hoffmann-La Roche Ag |
Kinase inhibitors
|
EP2229390B1
(en)
|
2007-12-14 |
2014-04-09 |
F. Hoffmann-La Roche AG |
Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives
|
CA2710462C
(en)
|
2008-02-05 |
2015-11-24 |
F. Hoffmann-La Roche Ag |
Pyridinones and pyridazinones
|
EP2297105B1
(en)
|
2008-05-06 |
2015-09-02 |
Gilead Connecticut, Inc. |
Substituted amides, method of making, and use as btk inhibitors
|
PE20100851A1
(es)
|
2008-06-24 |
2011-01-31 |
Hoffmann La Roche |
PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
|
US8450335B2
(en)
|
2008-06-27 |
2013-05-28 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
PE20110164A1
(es)
|
2008-07-02 |
2011-03-28 |
Hoffmann La Roche |
Nuevas fenilpirazinonas como inhibidores de quinasa
|
WO2010006947A1
(en)
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Novel phenyl-imidazopyridines and pyridazines
|
EP3311818A3
(en)
|
2008-07-16 |
2018-07-18 |
Pharmacyclics, LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
MX2010013190A
(es)
|
2008-07-18 |
2010-12-20 |
Hoffmann La Roche |
Fenilimidazopirazinas novedosas.
|
US8476430B2
(en)
|
2008-07-24 |
2013-07-02 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
WO2010028236A1
(en)
|
2008-09-05 |
2010-03-11 |
Avila Therapeutics, Inc. |
Algorithm for designing irreversible inhibitors
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
WO2010056875A1
(en)
|
2008-11-12 |
2010-05-20 |
Cgi Pharmaceuticals, Inc. |
Pyridazinones and their use as btk inhibitors
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
WO2010068788A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Heterocyclic amides as btk inhibitors
|
WO2010068810A2
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
MX2011006171A
(es)
|
2008-12-19 |
2011-06-20 |
Squibb Bristol Myers Co |
Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
|
EP3255047B1
(en)
|
2009-01-06 |
2021-06-30 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
|
WO2010092962A1
(ja)
|
2009-02-12 |
2010-08-19 |
アステラス製薬株式会社 |
へテロ環誘導体
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
ES2513915T3
(es)
|
2009-04-24 |
2014-10-27 |
F. Hoffmann-La Roche Ag |
Inhibidores de la tirosina quinasa de Bruton
|
JP5656976B2
(ja)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
ピロロトリアジン化合物
|
ES2444777T3
(es)
|
2009-06-12 |
2014-02-26 |
Bristol-Myers Squibb Company |
Compuestos de nicotinamida útiles como moduladores de quinasas
|
EP2464647B1
(en)
|
2009-08-11 |
2016-09-21 |
Bristol-Myers Squibb Company |
Azaindazoles as btk kinase modulators and use thereof
|
US9029359B2
(en)
|
2009-09-04 |
2015-05-12 |
Biogen Idec Ma, Inc. |
Heteroaryl Btk inhibitors
|
DK2473049T3
(en)
|
2009-09-04 |
2019-04-01 |
Biogen Ma Inc |
INHIBITORS OF BRUTON'S TYROSINKINASE
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
CA3034600C
(en)
|
2010-05-07 |
2020-11-10 |
Genentech, Inc. |
Pyridone and aza-pyridone compounds and methods of use
|
RS55184B1
(sr)
|
2010-05-31 |
2017-01-31 |
Ono Pharmaceutical Co |
Derivat purinona kao inhibitor btk kinaze
|
NZ736048A
(en)
|
2010-06-03 |
2019-09-27 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
WO2011159857A1
(en)
|
2010-06-16 |
2011-12-22 |
Bristol-Myers Squibb Company |
Carboline carboxamide compounds useful as kinase inhibitors
|
SI2975042T1
(sl)
|
2010-06-23 |
2019-02-28 |
Hanmi Science Co., Ltd. |
Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze
|
US20120053189A1
(en)
|
2010-06-28 |
2012-03-01 |
Pharmacyclics, Inc. |
Btk inhibitors for the treatment of immune mediated conditions
|
WO2012020762A1
(ja)
|
2010-08-10 |
2012-02-16 |
アステラス製薬株式会社 |
へテロ環化合物
|
EP2603081B1
(en)
|
2010-08-10 |
2016-10-05 |
Celgene Avilomics Research, Inc. |
Besylate salt of a btk inhibitor
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
ES2537190T3
(es)
|
2010-09-01 |
2015-06-03 |
Gilead Connecticut, Inc. |
Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas
|
BR112013007506A2
(pt)
|
2010-09-01 |
2016-07-12 |
Genentech Inc |
piridinonas/pirazinonas - métodos de criação e de uso
|
CA2831590A1
(en)
|
2011-03-28 |
2012-10-04 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
TWI572599B
(zh)
*
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(α-經取代之芳烷胺基及雜芳烷胺基)嘧啶基及1,3,5-三基苯并咪唑,其醫藥組合物及其在治療增生性疾病之用途
|
EP2691388A1
(en)
*
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
WO2012135801A1
(en)
|
2011-04-01 |
2012-10-04 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
CA2760174A1
(en)
|
2011-12-01 |
2013-06-01 |
Pharmascience Inc. |
Protein kinase inhibitors and uses thereof
|
JP5859640B2
(ja)
|
2011-05-17 |
2016-02-10 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ブルトンチロシンキナーゼ阻害剤
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
EA025496B1
(ru)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
EA027584B1
(ru)
|
2011-06-10 |
2017-08-31 |
Мерк Патент Гмбх |
Композиции и способы получения пиримидиновых и пиридиновых соединений с btk ингибирующей активностью
|
MX2014000338A
(es)
|
2011-07-08 |
2014-05-01 |
Novartis Ag |
Derivados de pirrolo-pirimidina novedoso.
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
RU2702908C2
(ru)
*
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
EP2989106B1
(en)
|
2013-04-25 |
2016-12-14 |
Beigene, Ltd. |
Fused heterocyclic compounds as protein kinase inhibitors
|
US20150005277A1
(en)
|
2013-06-28 |
2015-01-01 |
Beigene, Ltd. |
Protein Kinase Inhibitors and Uses Thereof
|
EP2832358A1
(en)
*
|
2013-08-02 |
2015-02-04 |
Bionsil S.r.l. |
Pharmaceutical kit for use in the treatment of colon and colorectal cancer
|
EA201691169A1
(ru)
|
2013-12-05 |
2016-09-30 |
Асерта Фарма Б.В. |
Терапевтическая комбинация ингибитора pi3k и ингибитора btk
|